alprenolol has been researched along with digoxin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Artursson, P; Bergström, CA; Matsson, P; Nagahara, N; Norinder, U; Tavelin, S | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Ekelund, LG; Johnsson, G; Melcher, A; Orö, L | 1 |
| Pedersen, F; Rasmussen, SL | 1 |
2 trial(s) available for alprenolol and digoxin
| Article | Year |
|---|---|
Effects of cedilanid-D and alprenolol in angina pectoris.
Topics: Alprenolol; Angina Pectoris; Blood Pressure; Cardiac Output; Cardiac Volume; Digoxin; Electrocardiography; Exercise Test; Female; Heart Ventricles; Hemodynamics; Humans; Lanatosides; Male; Middle Aged; Physical Exertion; Placebos; Time Factors | 1973 |
Short-term and long-term tolerance to beta-blockade with alprenolol in patients admitted for a suspected acute myocardial infarction.
Topics: Administration, Oral; Aged; Alprenolol; Arrhythmias, Cardiac; Blood Pressure; Clinical Trials as Topic; Digoxin; Diuretics; Drug Therapy, Combination; Heart Failure; Heart Rate; Humans; Injections, Intravenous; Middle Aged; Myocardial Infarction; Random Allocation; Time Factors | 1984 |
6 other study(ies) available for alprenolol and digoxin
| Article | Year |
|---|---|
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
Exploring the role of different drug transport routes in permeability screening.
Topics: Administration, Oral; Biological Transport; Caco-2 Cells; Cell Line; Humans; Intestinal Absorption; Intestinal Mucosa; Intestine, Small; Membranes, Artificial; Models, Biological; Molecular Conformation; Monte Carlo Method; Permeability; Pharmaceutical Preparations; Pharmacokinetics | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |